Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	₩3,175.00	-2.31%	90,516
11/09/26	₩3,250.00	-1.52%	110,363
10/09/26	₩3,300.00	-2.08%	173,838
09/09/26	₩3,370.00	+2.59%	92,230
08/09/26	₩3,285.00	-4.64%	137,131

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 14/09/2026			5-day change	1st Jan Change
3,175.00 ^KRW	-2.31%		-7.84%	-53.85%

04-13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
04-02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI

Market Cap	166B 123M 107M 101M 91.45M 172M 11.82B 173M 1.2B 464M 5.99B 463M 453M 19.06B	P/E 2024	-4.17x	P/E 2025	-33.5x
Enterprise Value	148B 110M 95.33M 89.96M 81.61M 153M 10.54B 154M 1.07B 414M 5.35B 413M 404M 17.01B	EV / Sales 2024	1.31x	EV / Sales 2025	8.97x
Free-Float	85.14%	Yield 2024 *	-	Yield 2025	-

04-13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
04-02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI
03-12	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
22/09/25	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index	CI
20/08/25	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.	CI
10/07/25	Genome & Company announced that it has received KRW 25.7890592 billion in funding	CI
27/04/25	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors	CI
23/04/25	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors	CI
23/04/25	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding	CI
23/04/25	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.	CI
18/07/24	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
16/07/24	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24/01/24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI

1 day	-2.31%
1 week	-7.84%
Current month	-15.45%
1 month	-31.28%
3 months	-41.20%
6 months	-63.17%
Current year	-53.85%

Genome & Company Share Price

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

Valuation: Genome & Company

Chart: Genome & Company

Latest news: Genome & Company

Quotes and Performance

Price Extremes

Managers and Directors: Genome & Company

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	3,120	3,425
1 month	3,120	4,625
Current year	2,975	10,180
1 year	2,470	10,180
3 years	2,170	10,180
5 years	2,170	23,700
10 years	2,170	47,500

Manager	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	53	23/09/2015
Ji-Soo Bae CEO	Chief Executive Officer	55	23/09/2015

Director	Title	Age	Since
Ji-Soo Bae BRD	Director/Board Member	55	23/09/2015
Han-Su Park BRD	Director/Board Member	53	23/09/2015
Yu-Seok Hong BRD	Director/Board Member	62	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/05/25	Han-Su Park	Don	Chief Executive Officer	100,000	0.3217%
09/05/25	Sang-Kyun Kim	Free	Director	40,000	0.1287%
09/05/25	Byung-Gyu Park	Free	Public Communications Manager	50,000	0.1608%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOME & COMPANY	-2.31%	-7.84%	+12.79%	-58.77%	123M
LONZA GROUP AG	-0.32%	-4.32%	-2.78%	+6.96%	45.63B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	43.96B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	43.73B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	40.23B
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	31.86B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.4B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	16.62B
EUROFINS SCIENTIFIC SE	+0.91%	+2.28%	+15.44%	+31.54%	14.46B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	13.04B
Average	+0.29%	-1.89%	+58.49%	+88.43%	26.7B
Weighted average by Cap.	+0.74%	-2.01%	+75.90%	+127.48%

	2024	2025
Net sales	27.74B 20.6M 17.85M 16.84M 15.28M 28.66M 1.97B 28.87M 201M 77.51M 1B 77.36M 75.66M 3.18B	24.59B 18.25M 15.82M 14.93M 13.54M 25.4M 1.75B 25.59M 178M 68.69M 888M 68.56M 67.05M 2.82B
Net income	-20.11B -14.93M -12.94M -12.21M -11.08M -20.78M -1.43B -20.93M -146M -56.19M -726M -56.08M -54.85M -2.31B	-6.43B -4.77M -4.14M -3.9M -3.54M -6.64M -457M -6.69M -46.61M -17.96M -232M -17.92M -17.53M -738M
Net Debt	-48.91B -36.31M -31.46M -29.69M -26.93M -50.53M -3.48B -50.89M -355M -137M -1.77B -136M -133M -5.61B	-17.86B -13.26M -11.49M -10.84M -9.84M -18.45M -1.27B -18.59M -130M -49.9M -645M -49.81M -48.71M -2.05B